Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Asymchem Laboratories (Tianjin) Co., Ltd. Class H ( (HK:6821) ) has shared an update.
Asymchem Laboratories (Tianjin) Co., Ltd. has adjusted the repurchase price for the first grant of restricted A shares under its 2025 A Share Restricted Share Incentive Scheme, following the approval and implementation of its 2024 profit distribution plan, which included a cash dividend of RMB11.00 per 10 shares. In line with the scheme’s terms, the repurchase price has been reduced from RMB37.52 to RMB36.42 per share to reflect the dividend payout, a change the company states will not have a material impact on its financial position or operating results; the adjustment has been endorsed by the Remuneration and Examination Committee and confirmed as compliant with relevant PRC regulations and stock exchange self-regulatory guidelines by the company’s legal advisers, underscoring the formal and regulatory soundness of its equity incentive management.
The most recent analyst rating on (HK:6821) stock is a Buy with a HK$98.40 price target. To see the full list of analyst forecasts on Asymchem Laboratories (Tianjin) Co., Ltd. Class H stock, see the HK:6821 Stock Forecast page.
More about Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. is a PRC-incorporated pharmaceutical group listed in Hong Kong, operating in the life sciences and drug development services industry. The company focuses on providing pharmaceutical research, development and manufacturing services, and has both A shares and H shares, reflecting its access to onshore and offshore capital markets.
Average Trading Volume: 357,799
Technical Sentiment Signal: Sell
Current Market Cap: HK$35.6B
Find detailed analytics on 6821 stock on TipRanks’ Stock Analysis page.

